Abbott/Murex
This article was originally published in The Gray Sheet
Executive Summary
The only rapid HIV test available on the U.S. market, the Abbott Murex Single Use Diagnostic System HIV-1 test, resumes availability after a seven months hiatus, FDA Center for Biologics Evaluation and Research announces May 10. Production was halted in October 2000 after a failure to meet certain panel and negative control specifications. After adding supplemental testing to ensure the product met its quality control specifications, CBER determined that five consecutive lots of the SUDS HIV-1 tests Abbott submitted could be released for clinical use
You may also be interested in...
CLIA Waiver, Oral Fluid Claim Next For HHS-Backed OraQuick Rapid HIV Test
OraSure and FDA are discussing a CLIA waiver protocol the company has submitted for its OraQuick rapid HIV diagnostic test, which gained premarket approval Nov. 7
CLIA Waiver, Oral Fluid Claim Next For HHS-Backed OraQuick Rapid HIV Test
OraSure and FDA are discussing a CLIA waiver protocol the company has submitted for its OraQuick rapid HIV diagnostic test, which gained premarket approval Nov. 7
CDC Selects OraSure's OraQuick Rapid HIV-1/2 Test for MIRIAD Project
OraSure Technologies is hoping that the Centers for Disease Control and Prevention's inclusion of the OraQuick rapid HIV-1/2 test in a maternal AIDS intervention study will raise the product's visibility among U.S. public hospitals.